Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Febuxostat (Primary) ; Verinurad (Primary)
- Indications Hyperuricaemia; Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 14 Jun 2017 Planned End Date changed from 29 Jun 2018 to 28 Jun 2018.
- 14 Jun 2017 Planned primary completion date changed from 23 Mar 2018 to 15 Mar 2018.
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.